Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Freshpet Inc CS (NQ: FRPT )

133.69 +1.15 (+0.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Freshpet Inc CS

< Previous 1 2 3 4 5 6 7 Next >
Freshpet's Visibility Of Margin Improvement Makes This Analyst Remain Bullish On The Stock
Via Benzinga
Chewy Stock: Bull vs. Bear
Is the pet products retailer a buy? See what the bulls and bears have to say. 
Via The Motley Fool
Analyst Ratings for Freshpet
Via Benzinga
Lyft Price Target Cut By 56%; Plus Piper Sandler Sees $61 For Five9
Evercore ISI Group cut the price target on Lyft, Inc. (NASDAQ: LYFT) from $41 to $18. Lyft shares fell 17.1% to $11.72 on Tuesday. 
Via Benzinga
What 13 Analyst Ratings Have To Say About Freshpet
Within the last quarter, Freshpet (NASDAQ:FRPT) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022
Upgrades 
Via Benzinga
Expert Ratings for Freshpet
Within the last quarter, Freshpet (NASDAQ:FRPT) has observed the following analyst ratings: 
Via Benzinga
Freshpet (FRPT) Q3 2022 Earnings Call Transcript
FRPT earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Freshpet: A Fresh Time To Buy Into This Growth Story?
Freshpet is pulling back after a weaker-than-expected report but there are signs the stock is bottoming and expected improvements in the margin is coming. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Jim Cramer Says Freshpet Is 'Too Expensive,' This Stock Has 'A Better Pet Food Division'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Freshpet, Inc. (NASDAQ: FRPT) is "too expensive." He said General Mills, Inc. 
Via Benzinga
Short Interest Sector Focus: Consumer Defensive Sector
As of the close of business on Tuesday, 10/11, we captured the Top 10 Highest Short Interest % stocks within the Consumer Defensive Sector. The average short interest for stocks within the Consumer... 
Via Benzinga
Expert Ratings for Freshpet
Over the past 3 months, 11 analysts have published their opinion on Freshpet (NASDAQ:FRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
What 10 Analyst Ratings Have To Say About Freshpet
Analysts have provided the following ratings for Freshpet (NASDAQ:FRPT) within the last quarter: 
Via Benzinga
Freshpet Finance Chief Steps Down; Co. Reaffirms FY22 Outlook
Via Benzinga
Analyst Ratings for Freshpet
  Within the last quarter, Freshpet (NASDAQ:FRPT) has observed the following analyst ratings: 
Via Benzinga
Freshpet: Q2 Earnings Insights
  Freshpet (NASDAQ:FRPT) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Freshpet reported an EPS of $-0.45. 
Via Benzinga
Where Freshpet Stands With Analysts
Over the past 3 months, 11 analysts have published their opinion on Freshpet (NASDAQ:FRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2022
Upgrades 
Via Benzinga
Will Activist Investors Change the Game for Freshpet (FRPT) Stock?
Freshpet (FRPT) stock is rallying on Friday as traders look to news of an activist stake in the company as a potential positive. 
Via InvestorPlace
7 Kim Kardashian Stocks to Buy
These Kim Kardashian Stocks to Buy are what's Kimmie's new equity firm is all about. There's no reason she won't succeed here as well. 
Via InvestorPlace
Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2022
  
Via Benzinga
Short Interest Sector Focus: Consumer Defensive Sector
As of the close of business on Wednesday, 8/25, we captured the Top 10 Highest Short Interest % stocks within the Consumer Defensive Sector. The average short interest for stocks within the Consumer... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 18, 2022
  
Via Benzinga
Your Pet Or Car? When Times Got Rough, Consumers Made A Tough Choice This Summer
Freshpet Inc’s (NASDAQ: FRPT) second-quarter earnings report offered great insight into the current macroeconomic trends currently affecting the pockets of Americans. 
Via Benzinga
Micron Technology, Novavax, CarGurus And Some Other Big Losers From Tuesday
U.S. stocks closed lower, with the Nasdaq dropping 150 points on Tuesday. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
Short Interest Sector Focus: Consumer Defensive Sector
As of the close of business on Friday, 7/22, we captured the Top 10 Highest Short Interest % stocks within the Consumer Defensive Sector. The average short interest for stocks within the Consumer... 
Via Benzinga
He Predicted Fall Of WeWork And Rivian, Now This Analyst Warns These 3 Stocks Are Set To Implode
While there’s no shortage of Wall Street analysts who will argue the bull case for stocks, there are just a few who are willing to put their reputations on the line and call out companies that will... 
Via Benzinga
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method. 
Via Benzinga
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD.... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.